GB2330533B - Composition for enhanced uptake of polar drugs from mucosal surfaces - Google Patents

Composition for enhanced uptake of polar drugs from mucosal surfaces

Info

Publication number
GB2330533B
GB2330533B GB9900050A GB9900050A GB2330533B GB 2330533 B GB2330533 B GB 2330533B GB 9900050 A GB9900050 A GB 9900050A GB 9900050 A GB9900050 A GB 9900050A GB 2330533 B GB2330533 B GB 2330533B
Authority
GB
United Kingdom
Prior art keywords
composition
mucosal surfaces
enhanced uptake
polar drugs
polar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9900050A
Other versions
GB2330533A (en
GB9900050D0 (en
Inventor
Lisbeth Illum
Peter James Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst UK Ltd, West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd filed Critical Danbiosyst UK Ltd
Publication of GB9900050D0 publication Critical patent/GB9900050D0/en
Publication of GB2330533A publication Critical patent/GB2330533A/en
Application granted granted Critical
Publication of GB2330533B publication Critical patent/GB2330533B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
GB9900050A 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces Expired - Fee Related GB2330533B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9614235.1A GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces
PCT/GB1997/001852 WO1998001159A2 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces

Publications (3)

Publication Number Publication Date
GB9900050D0 GB9900050D0 (en) 1999-02-24
GB2330533A GB2330533A (en) 1999-04-28
GB2330533B true GB2330533B (en) 2000-10-25

Family

ID=10796483

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9614235.1A Pending GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces
GB9900050A Expired - Fee Related GB2330533B (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB9614235.1A Pending GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces

Country Status (8)

Country Link
EP (1) EP0993305A2 (en)
JP (1) JP2000515503A (en)
KR (1) KR20000023583A (en)
AU (1) AU722724B2 (en)
CA (1) CA2257563A1 (en)
GB (2) GB9614235D0 (en)
NO (1) NO985956D0 (en)
WO (1) WO1998001159A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
CA2363123C (en) * 1999-02-22 2011-09-06 Kenneth Iain Cumming Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
AU2003302888A1 (en) * 2002-12-11 2004-06-30 Chong Kun Dang Pharmaceutical Corp. Oral formulations for poorly absorptive hydrophilic drugs
DE102004027924A1 (en) * 2004-06-09 2005-12-29 Röhm GmbH & Co. KG Pharmaceutical form containing the active ingredient cholylsarcosine
ES2426445T3 (en) 2006-04-07 2013-10-23 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
TW200950801A (en) 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of peptides and processes of preparation thereof
EP2442821B1 (en) 2009-06-18 2017-06-14 Allergan, Inc. Safe desmopressin administration
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
KR20140026354A (en) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 Pharmaceutical compositions of iron for oral administration
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
CN108201531A (en) * 2016-12-19 2018-06-26 湖南尔康湘药制药有限公司 Segmented intestine targeted starch capsule of highly dissoluble sulbenicillin sodium and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007923A1 (en) * 1989-01-19 1990-07-26 California Biotechnology Inc. Transmembrane formulations for drug administration
DE4222647A1 (en) * 1991-07-15 1993-01-21 Sandoz Ag PEPTIDE PREPARATIONS
WO1995001183A1 (en) * 1993-06-29 1995-01-12 Ferring B.V. Compositions for nasal administration of desmopressin
WO1997006813A1 (en) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Mucosal preparation containing physiologically active peptide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007923A1 (en) * 1989-01-19 1990-07-26 California Biotechnology Inc. Transmembrane formulations for drug administration
DE4222647A1 (en) * 1991-07-15 1993-01-21 Sandoz Ag PEPTIDE PREPARATIONS
WO1995001183A1 (en) * 1993-06-29 1995-01-12 Ferring B.V. Compositions for nasal administration of desmopressin
WO1997006813A1 (en) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Mucosal preparation containing physiologically active peptide

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Chemical Abstract à 112:42406 & Congr. Int. Technol. Pharm.,1989, 1, 91-98 (NAGAI et al.), *
Chemical Abstract à 95:109081 & Life Sci., 1981, 29(8), 803-809, (ZIV et al.) *
Chemical Abstract à 98:191258 & Biochem. Pharmacol., 1983, 32(5), 773-776 (ZIV et al.) *
Int. J. Pharm., 1991, 74(2-3), 95-103, (UCHIDA et al.) "Influence of Bile....Derivatives". *
J. Controlled Release, 1997, 46(1/02), 17-30 (KRAMER et al.)"Modified Bile.....Peptides and Drugs". *
J. Pharm. Sci., 1987, 76(5), 351-355, (LONGENECKER et al.) "Effects of ....Insulin in Sheep". *
J. Pharm. Sci., 1994, 83(10), 1465-1469, (SCOTT-MONCRIEFF etal.) "Enhancement...Micelles in Dogs". *
J. Pharmacobio-Dyn., 1988, 11(6), 395-401, (NAKADA et al.) "The Effect of Additives....in Rats". *
J. Pharmacobio-Dyn., 1989, 12(12), 736-743, (NAKADA et al.) "The Effect of Bile..Calcitonin in Rats" *
J. Pharmacol. Exp. Ther., 1988, 244(1), 23-28,(AUNGST et al)"Comparison...Absorption Promoter". *
Proc. Natl. Acad. Sci. USA, 1985, 82(21), 7419-7423 (GORDON et al.), "Nasal....Bile Salts". *

Also Published As

Publication number Publication date
AU722724B2 (en) 2000-08-10
NO985956L (en) 1998-12-18
GB2330533A (en) 1999-04-28
NO985956D0 (en) 1998-12-18
EP0993305A2 (en) 2000-04-19
WO1998001159A2 (en) 1998-01-15
AU3453997A (en) 1998-02-02
JP2000515503A (en) 2000-11-21
CA2257563A1 (en) 1998-01-15
WO1998001159A3 (en) 1998-03-26
KR20000023583A (en) 2000-04-25
GB9900050D0 (en) 1999-02-24
GB9614235D0 (en) 1996-09-04

Similar Documents

Publication Publication Date Title
IL133420A0 (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
IL181059A0 (en) Pharmaceutical compositions containing isoflavones
GB9600426D0 (en) Compositions
EG24118A (en) Pharmaceutical compositions
IL127684A0 (en) Composition for appetite suppression
GB2330533B (en) Composition for enhanced uptake of polar drugs from mucosal surfaces
GB9616672D0 (en) Pharmaceutical compositions
ZA9710006B (en) Novel pharmaceutical compositions
GB9610359D0 (en) Pharmaceutical compositions
EP0885896A4 (en) Phospholipid composition
GB9622681D0 (en) Pharmaceutical compositions
KR100207900B1 (en) Dielectric ceramic composition
GB9606429D0 (en) Pharmaceutical compositions
SG50003A1 (en) Dielectric ceramics composition
PL337804A1 (en) Solubilised compositions of sertralin
GB9613457D0 (en) Pharmaceutical compositions
GB9623962D0 (en) Pharmaceutical composition
GB9618964D0 (en) Oral composition
GB9610136D0 (en) Pharmaceutical compositions
GB9614188D0 (en) Ceramic compositions
HUP0003528A3 (en) Pharmaceutical compositions containing dihydropolyprenols
EP0906085A4 (en) Compositions
SI0941095T1 (en) Improved pharmaceutical compositions
GB9606586D0 (en) Pharmaceutical compositions
GB9603942D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20020707